Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DalCor Pharmaceuticals
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.
Repurposed drugs, new compounds and neutralizing antibodies are among the targets of a new collaborative venture supported by Europe’s Innovative Medicines Initiative.
Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.
Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health
This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.
- In Vitro Diagnostics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.